June 22, 2009
Since 2001, when Accera was founded, the company has been developing solutions for neurological degenerative disorders, especially Alzheimer’s Disease. After years of research, in March 3, 2009, Accera released its first product to market, Axona. Axona is not another drug, it is a medical dietary supplement for those suffering from mild to moderate Alzheimer’s disease.
How does Axona work? Simple. To understand how Axona works, you must first understand Alzheimer’s disease. According to Accera’s company website, Alzheimer’s disease is caused when the patient’s body is not able to metabolize glucose in the brain. Glucose, the scientific term for sugar, is the main fuel for the brain. Glucose is found in a wide variety of natural products from fruits and vegetables to meat and fish. Studies show that the brains of Alzheimer’s patients are not metabolizing the necessary amount of glucose to prevent the symptoms of Alzheimer’s disease. Until the advent of Axona, Alzheimer’s disease has largely remained untreated, leaving Alzhaimer’s patients to a bleak future with independent living not being an option anymore.
Some of the common symptoms of Alzheimer’s disease is that the afflicted person is unable to remember certain things and not being able to function properly in everyday life. In the more severe cases of Alzheimer’s disease, the afflicted cannot live by himself and needs round the clock care.
The way Axona works is that it is a special dietary medical food that provides the brain with the nutrients it needs to deter the further degradation that is synonymous with Alzheimer’s disease.
Though the Axona dietary treatment is already on the market and is having amazing results with patients suffering from mild to moderate Alzheimer’s disease, Accera is also working on therapies for other neurological disorders as well.
Along with Axona, Accera also has a therapy, that is currently undergoing clinical trials, to cure age-associated memory impairment. Furthermore, the company is researching different therapies for treating both Huntington’s and Parkinson’s diseases.
The founder of Accera is Dr. Steve A. Orndorff, who also continues to serves the company as its president and CEO. Dr. Orndorff is a seasoned entrepreneur with over 25 years of experience with biotechnology. Dr. Orndorff also worked at Univera Pharmaceuticals, Inc., where he also served as the company’s president and CEO. Univera Pharmaceuticals is a pharmaceutical company that develops solutions for inflammation and immune disorders. Dr. Orndorff also worked on other projects as well, such as research that led to the development of NutraSweet, Inc.
Accera is based in Broomfield, Colorado and employs 10 people.
Accera’s investors include Inventages Venture Capital and POSCO BioVentures, who both participated in the company’s seed and series A funding rounds.
Inventages Venture Partners was founded in 2000 and is a vc firm that is dedicated to the life sciences and biotech industries. The vc firm will aso fund companies that have a treatment which is effective and serves an unmet need. Inventages is a global vc firm is global with offices in Geneva, Switzerland; Nassau, Bahamas; and Aukland, New Zealand. Other companies in Inventages’ portfolio include AM Pharma, Atonomis, Biolactic, Boowl, Cavis, and others.
POSCO BioVentures is a vc firm that is solely dedicated to the biotech industry. POSCO is the brainchild of Dr. Leo Kim, PhD and the vc firm will invest in companies that have a promising effect in the health department. Some other companies in POSCO’s portfolio include Acorda, Anadys, Bioarray Solutions, and others.
Accera does not have any known competitors
For more information about Accera, click here.